AbbVie Upgraded On $7.8 Billion Imbruvica Potential

By | April 13, 2015

Scalper1 News

Big pharma AbbVie (ABBV) got an upgrade Monday from BMO Capital Markets, which warmed to the potential of its pending acquisition. Analyst Alex Arfaei upgraded AbbVie to outperform from market perform, saying that growing awareness of biosimilar competition for flagship drug Humira have driven down the stock to reasonable levels. At the same time, he was overcoming his initial skepticism toward AbbVie’s $21 billion payout to acquire Pharmacyclics Scalper1 News

Scalper1 News